Ropes & Gray advised Alexion Pharmaceuticals in a collaboration and license agreement with Halozyme Therapeutics that enables Alexion to use Halozyme’s ENHANZE drug delivery technology in the development of subcutaneous formulations for Alexion’s rare disease drug product portfolio.
The licensing agreement allows Alexion to exclusively develop up to four disease targets, including next generation subcutaneous formulation for the company’s investigational long-acting C5 protein complement inhibitor, to potentially further extend the drug dosing interval to once every two weeks or once per month.
Under terms of the agreement, Halozyme will receive an initial $40 million with the potential to earn additional payments of up to $160 million for each target developed, subject to achievement of specified development, regulatory and sales milestones. Halozyme will also receive mid-single digit royalties on sales of commercial products.
The Ropes & Gray team included life sciences partner Susan Galli (Picture) and associate Abigail Gregor and corporate practice associates Liam O’Sullivan and Jessica DeLalio (all of Boston).
Law Firms: Ropes & Gray;
Clients: Alexion Pharmaceuticals;